Streptococcus pneumoniae, also known as the pneumococcus, is an important cause of morbidity and mortality in the developed and developing world. Pneumococcal conjugate vaccines were first introduced for routine use in the USA in 2000, although the seven-valent pneumococcal conjugate vaccine (PCV7) was not introduced into the UK's routine childhood immunization programme until September 2006. After its introduction, a marked decrease in the incidence of pneumococcal disease was observed, both in the vaccinated and unvaccinated UK populations. However, pneumococci are highly diverse and serotype prevalence is dynamic. Conversely, PCV7 targets only a limited number of capsular types, which appears to confer a limited lifespan to the observed beneficial effects. Shifts in serotype distribution have been detected for both non-invasive and invasive disease reported since PCV7 introduction, both in the UK and elsewhere. The pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix; GlaxoSmithKline) and 13-valent pneumococcal conjugate vaccine (PCV13, Prevenar 13; Pfizer) have been newly licensed. The potential coverage of the 10- and 13-valent conjugate vaccines has also altered alongside serotype shifts. Nonetheless, the mechanism of how PCV7 has influenced serotype shift is not clear-cut as the epidemiology of serotype prevalence is complex. Other factors also influence prevalence and incidence of pneumococcal carriage and disease, such as pneumococcal diversity, levels of antibiotic use and the presence of risk groups. Continued surveillance and identification of factors influencing serotype distribution are essential to allow rational vaccine design, implementation and continued effective control of pneumococcal disease.
BättigP.,
HathawayL. J.,
HoferS.,
MühlemannK.2006; Serotype-specific invasiveness and colonization prevalence in Streptococcus pneumoniae correlate with the lag phase during in vitro growth. Microbes Infect 8:2612–2617[CrossRef]
BlackS. B. M.,
ShinefieldH. R. M.,
LingS. M. M.,
HansenJ.,
FiremanB. M.,
SpringD. M.,
NoyesJ. M.,
LewisE. M.,
RayP. M.other authors2002; Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21:810–815[CrossRef]
BlackS.,
ShinefieldH.,
BaxterR.,
AustrianR.,
BrackenL.,
HansenJ.,
LewisE.,
FiremanB.2004; Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 23:485–489[CrossRef]
BrueggemannA. B.,
GriffithsD. T.,
MeatsE.,
PetoT. E.,
CrookD. W.,
SprattB. G.2003; Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 187:1424–1432[CrossRef]
BrueggemannA. B.,
PetoT. E.,
CrookD. W.,
ButlerJ. C.,
KristinssonK. G.,
SprattB. G.2004; Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 190:1203–1211[CrossRef]
CaoJ.,
ChenD.,
XuW.,
ChenT.,
XuS.,
LuoJ.,
ZhaoQ.,
LiuB.,
WangD.other authors2007; Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP. Vaccine 25:4996–5005[CrossRef]
CaoJ.,
LiD.,
GongY.,
YinN.,
ChenT.,
WongC. K.,
XuW.,
LuoJ.,
ZhangX.other authors2009; Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection. Clin Exp Immunol 156:52–60[CrossRef]
CaseyJ. R.,
AdlowitzD. G.,
PichicheroM. E.2010; New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 29:304–309
CDC2005; Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb Mortal Wkly Rep 54:893–897
CDC2009; Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine – United States, 1997–2006. MMWR Morb Mortal Wkly Rep 58:1–4
ClarkeS. C.,
JefferiesJ. M.,
SmithA. J.,
McMenaminJ.,
MitchellT. J.,
EdwardsG. F. S.2006; Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in Scotland. J Clin Microbiol 44:1224–1228[CrossRef]
CoffeyT. J.,
EnrightM. C.,
DanielsM.,
MoronaJ. K.,
MoronaR.,
HryniewiczW.,
PatonJ. C.,
SprattB. G.1998; Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae
. Mol Microbiol 27:73–83[CrossRef]
Committee on Infectious Diseases2000; Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 106:362–366[CrossRef]
DaganR.,
Givonâ-LaviN.,
LeibovitzE.,
GreenbergD.,
PoratN.2009; Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 199:776–785[CrossRef]
EskolaJ.,
KilpiT.,
PalmuA.,
JokinenJ.,
HaapakoskiJ.,
HervaE.,
TakalaA.,
KayhtyH.,
KarmaP.other authors2001; Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344:403–409[CrossRef]
GrijalvaC. G.,
NuortiJ. P.,
ArbogastP. G.,
MartinS. W.,
EdwardsK. M.,
GriffinM. R.2007; Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369:1179–1186[CrossRef]
HanageW. P.,
KaijalainenT. H.,
SyrjanenR. K.,
AuranenK.,
LeinonenM.,
MakelaP. H.,
SprattB. G.2005; Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland. Infect Immun 73:431–435[CrossRef]
HausdorffW. P.,
BryantJ.,
ParadisoP. R.,
SiberG. R.2000; Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30:100–121[CrossRef]
HausdorffW. P.,
DaganR.,
BeckersF.,
SchuermanL.2009; Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine 27:7257–7269[CrossRef]
HicksL. A.,
HarrisonL. H.,
FlanneryB.,
HadlerJ. L.,
SchaffnerW.,
CraigA. S.,
JacksonD.,
ThomasA.,
BeallB.other authors2007; Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis 196:1346–1354[CrossRef]
HussainM.,
MelegaroA.,
PebodyR. G.,
GeorgeR.,
EdmundsW. J.,
TalukdarR.,
MartinS. A.,
EfstratiouA.,
MillerE.2005; A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect 133:891–898[CrossRef]
JefferiesJ. M.,
SmithA. J.,
EdwardsG. F. S.,
McMenaminJ.,
MitchellT. J.,
ClarkeS. C.2010; Temporal analysis of invasive pneumococcal clones from Scotland illustrates fluctuations in diversity of serotype and genotype in the absence of pneumococcal conjugate vaccine. J Clin Microbiol 48:87–96[CrossRef]
KayeP.,
MalkaniR.,
MartinS.,
SlackM.,
TrotterC.,
JitM.,
GeorgeR.,
MillerE.2009; Invasive pneumococcal disease (IPD) in England & Wales after 7-valent conjugate vaccine (PCV7); potential impact of 10 and 13-valent vaccines. Presented at The 27th Annual Meeting of the European Society for Paediatric Infectious Diseases 9–13 June 2009 Brussels:
KieningerD. M.,
KueperK.,
SteulK.,
JuergensC.,
AhlersN.,
BakerS.,
GiardinaP.,
GruberW.,
ScottD.2008; Safety and immunologic non-inferiority of 13-valent pneumococcal conjugate vaccine compared to 7-valent pneumococcal conjugate vaccine given as a 4-dose series with routine vaccines in healthy infants and toddlers. Presented at The 48th Annual ICAAC/IDSA 46th Annual Meeting 25–28 October 2008 Washington DC:
KyawM. H.,
ChristieP.,
ClarkeS. C.,
MooneyJ. D.,
AhmedS.,
JonesI. G.,
CampbellH.2003; Invasive pneumococcal disease in Scotland, 1999–2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin Infect Dis 37:1283–1291[CrossRef]
LeeH.,
NahmM. H.,
BurtonR.,
KimK.2009; Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol 16:376–381[CrossRef]
LuceroM. G.,
DulaliaV. E.,
NillosL. T.,
WilliamsG.,
ParrenoR. A.,
NohynekH.,
RileyI. D.,
MakelaH.2009; Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev CD004977
McEllistremM. C.,
AdamsJ.,
MasonE. O.,
WaldE. R.2003; Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine. J Infect Dis 188:1679–1684[CrossRef]
MelegaroA.,
EdmundsW. J.,
PebodyR.,
MillerE.,
GeorgeR.2006; The current burden of pneumococcal disease in England and Wales. J Infect 52:37–48[CrossRef]
NahmM. H.,
LinJ.,
FinkelsteinJ. A.,
PeltonS. I.2009; Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis 199:320–325[CrossRef]
OgunniyiA. D.,
GrabowiczM.,
BrilesD. E.,
CookJ.,
PatonJ. C.2007; Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae
. Infect Immun 75:350–357[CrossRef]
ParkI. H.,
PritchardD. G.,
CarteeR.,
BrandaoA.,
BrandileoneM. C. C.,
NahmM. H.2007b; Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae
. J Clin Microbiol 45:1225–1233[CrossRef]
PichonB.,
BeasleyL.,
SlackM.,
EfstratiouA.,
MillerE.,
GeorgeR.2008; Effect of the introduction of the pneumococcal conjugate vaccine in the UK childhood immunisation scheme on the genetic structure of paediatric invasive pneumococci. In The 6th International Symposium on Pneumococci and Pneumococcal Diseases 8–12 June 2008 Reykjavik, Iceland:
PletzM. W.,
MausU.,
KrugN.,
WelteT.,
LodeH.2008; Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 32:199–206[CrossRef]
PrymulaR.,
PeetersP.,
ChrobokV.,
KrizP.,
NovakovaE.,
KaliskovaE.,
KohlI.,
LommelP.,
PoolmanJ.other authors2006; Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae : a randomised double-blind efficacy study. Lancet 367:740–748[CrossRef]
RennelsM. B.,
EdwardsK. M.,
KeyserlingH. L.,
ReisingerK. S.,
HogermanD. A.,
MadoreD. V.,
ChangI.,
ParadisoP. R.,
MalinoskiF. J.other authors1998; Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101:604–611[CrossRef]
RodgersG. L.,
ArguedasA.,
CohenR.,
DaganR.2009; Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 27:3802–3810[CrossRef]
Sá-LeãoR.,
NunesS.,
Brito-AvôA.,
FrazãoN.,
SimõesA. S.,
CrisóstomoM. I.,
PauloA. C. S.,
SaldanhaJ.,
Santos-SanchesI.other authors2009; Changes in pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with widespread use of the seven-valent pneumococcal conjugate vaccine. Clin Microbiol Infect 15:1002–1007[CrossRef]
ScottD. A.,
KomjathyS. F.,
HuB. T.,
BakerS.,
SupanL. A.,
MonahanC. A.,
GruberW.,
SiberG. R.,
LockhartS. P.2007; Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25:6164–6166[CrossRef]
SilvaN. A.,
McCluskeyJ.,
JefferiesJ. M. C.,
HindsJ.,
SmithA.,
ClarkeS. C.,
MitchellT. J.,
PatersonG. K.2006; Genomic diversity between strains of the same serotype and multilocus sequence type among pneumococcal clinical isolates. Infect Immun 74:3513–3518[CrossRef]
SmithT.,
LehmannD.,
MontgomeryJ.,
GrattenM.,
RileyI. D.,
AlpersM. P.1993; Acquisition and invasiveness of different serotypes of Streptococcus pneumoniae in young children. Epidemiol Infect 111:27–39[CrossRef]
VäkeväinenM.,
EklundC.,
EskolaJ.,
KäyhtyH.2001; Cross-reactivity of antibodies to Type 6B and 6A polysaccharides of Streptococcus pneumoniae , evoked by pneumococcal conjugate vaccines, in infants. J Infect Dis 184:789–793[CrossRef]
WysockiJ.,
TejedorJ. C.,
GrunertD.,
KoniorR.,
Garcia-SiciliaJ.,
KnufM.,
BernardL.,
DieussaertI.,
SchuermanL.2009; Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 28:S77–S88[CrossRef]
ZhangQ.,
ChooS.,
FinnA.2002; Immune responses to novel pneumococcal proteins Pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children. Infect Immun 70:5363–5369[CrossRef]